Literature DB >> 17936901

Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes.

Chikako Satoh1, Kazuo Dan, Taishi Yamashita, Risa Jo, Hideto Tamura, Kiyoyuki Ogata.   

Abstract

Recent studies have suggested that flow cytometry (FCM) helps diagnose myelodysplastic syndromes (MDS). However, appropriate FCM diagnostic parameters that are easily reproducible by different examiners remain unclarified. We found that "the Ly/Mbl CD45 ratio (mean fluorescence intensity [MFI] of CD45 on lymphocytes/MFI of CD45 on CD34+ myeloblasts)," "the percentage of CD34+ myeloblasts among all nucleated cells," and "the percentage of CD34+ B-cell precursors among all CD34+ cells" had little interexaminer variability. These parameters can be analyzed from one test tube for three-color FCM, and their analysis in combination can diagnose a certain percentage of low-grade MDS patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936901     DOI: 10.1016/j.leukres.2007.08.022

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  Rapid cell population identification in flow cytometry data.

Authors:  Nima Aghaeepour; Radina Nikolic; Holger H Hoos; Ryan R Brinkman
Journal:  Cytometry A       Date:  2011-01       Impact factor: 4.355

2.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Authors:  Matteo G Della Porta; Cristina Picone; Cristiana Pascutto; Luca Malcovati; Hideto Tamura; Hiroshi Handa; Magdalena Czader; Sylvie Freeman; Paresh Vyas; Anna Porwit; Leonie Saft; Theresia M Westers; Canan Alhan; Claudia Cali; Arjan A van de Loosdrecht; Kiyoyuki Ogata
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission.

Authors:  Sung-Chao Chu; Tso-Fu Wang; Yu-Chieh Su; Ruey-Ho Kao; Yi-Feng Wu; Dian-Kun Li; Szu-Chin Li; Chi-Cheng Li; Denise A Wells; Michael R Loken
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

4.  Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.

Authors:  Nicolas Goardon; Emmanouil Nikolousis; Alexander Sternberg; Wai-Kit Chu; Charles Craddock; Peter Richardson; Richard Benson; Mark Drayson; Graham Standen; Paresh Vyas; Sylvie Freeman
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

5.  Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.

Authors:  Kiyoyuki Ogata; Matteo G Della Porta; Luca Malcovati; Cristina Picone; Norio Yokose; Akira Matsuda; Taishi Yamashita; Hideto Tamura; Junichi Tsukada; Kazuo Dan
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

6.  Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.

Authors:  Suiellen C Reis-Alves; Fabiola Traina; Konradin Metze; Irene Lorand-Metze
Journal:  Diagn Pathol       Date:  2015-04-29       Impact factor: 2.644

Review 7.  Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.

Authors:  Matteo G Della Porta; Cristina Picone
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-02-15       Impact factor: 2.576

8.  Implementation of the Ogata flow cytometric scoring system in routine diagnostics of myelodysplastic syndrome.

Authors:  Sara Maj Hyldig Matzen; Klas Kræsten Raaschou-Jensen; Klaus Kallenbach
Journal:  Health Sci Rep       Date:  2018-09-26

9.  Merging mixture components for cell population identification in flow cytometry.

Authors:  Greg Finak; Ali Bashashati; Ryan Brinkman; Raphaël Gottardo
Journal:  Adv Bioinformatics       Date:  2009-11-12

10.  Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.

Authors:  Suiellen C Reis-Alves; Fabíola Traina; Guilherme Harada; Paula M Campos; Sara T O Saad; Konradin Metze; Irene Lorand-Metze
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.